J W Hay

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Evaluation and review of pharmacoeconomic models
    Joel W Hay
    University of Southern California, Department of Pharmaceutical Economics and Policy, CA, USA
    Expert Opin Pharmacother 5:1867-80. 2004
  2. pmc Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid
    Vaidyanathan Ganapathy
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California, 3335 S Figueroa Street, Unit A, Los Angeles, CA 90089 7273, USA
    BMC Pediatr 13:127. 2013
  3. ncbi request reprint Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 7273, USA
    Haemophilia 19:711-9. 2013
  4. pmc Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes
    Joel W Hay
    Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA 90089, USA
    Value Health 15:249-54. 2012
  5. ncbi request reprint Economic considerations for pertussis booster vaccination in adolescents
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 USA
    Pediatr Infect Dis J 24:S127-33. 2005
  6. ncbi request reprint Cost and utilization impacts of oral antihistamines in the California Medi-Cal program
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089, USA
    Value Health 8:506-16. 2005
  7. doi request reprint Cost impact of diagnostic imaging for lower extremity peripheral vascular occlusive disease
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 12:262-6. 2009
  8. doi request reprint Using pharmacoeconomics to value pharmacotherapy
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
    Clin Pharmacol Ther 84:197-200. 2008
  9. doi request reprint Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective
    Joel W Hay
    University of Southern California Center for the Health Professions, Los Angeles, CA 90033, USA
    Curr Med Res Opin 25:1421-31. 2009
  10. doi request reprint Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I
    Joel W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 13:3-7. 2010

Detail Information

Publications34

  1. ncbi request reprint Evaluation and review of pharmacoeconomic models
    Joel W Hay
    University of Southern California, Department of Pharmaceutical Economics and Policy, CA, USA
    Expert Opin Pharmacother 5:1867-80. 2004
    ..This review describes and evaluates the common types of pharmacoeconomic models, modelling approaches and methods. It also discusses model quality, validity and usefulness...
  2. pmc Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid
    Vaidyanathan Ganapathy
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California, 3335 S Figueroa Street, Unit A, Los Angeles, CA 90089 7273, USA
    BMC Pediatr 13:127. 2013
    ..This paper compares the long term healthcare costs beyond the initial hospitalization period incurred by medical and surgical NEC survivors with that of matched controls without a diagnosis of NEC during birth hospitalization...
  3. ncbi request reprint Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 7273, USA
    Haemophilia 19:711-9. 2013
    ..Use of bypass therapy assay testing before treatment administration in haemophilia inhibitor patients can potentially reduce treatment costs significantly while optimizing dose and therapy response...
  4. pmc Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes
    Joel W Hay
    Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA 90089, USA
    Value Health 15:249-54. 2012
    ..To evaluate the cost-effectiveness of a socioculturally adapted collaborative depression care program among low-income Hispanics with diabetes...
  5. ncbi request reprint Economic considerations for pertussis booster vaccination in adolescents
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 USA
    Pediatr Infect Dis J 24:S127-33. 2005
    ..These new vaccines for adolescents and adults are safe, immunogenic, and protective...
  6. ncbi request reprint Cost and utilization impacts of oral antihistamines in the California Medi-Cal program
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089, USA
    Value Health 8:506-16. 2005
    ..There are no empirical studies comparing the costs of treatment of SGAs relative to FGAs...
  7. doi request reprint Cost impact of diagnostic imaging for lower extremity peripheral vascular occlusive disease
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 12:262-6. 2009
    ..The objective of this study is to assess and compare costs associated with diagnostic imaging in peripheral vascular occlusive disease (PAOD)...
  8. doi request reprint Using pharmacoeconomics to value pharmacotherapy
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics, and Policy, University of Southern California, Los Angeles, California, USA
    Clin Pharmacol Ther 84:197-200. 2008
    ....
  9. doi request reprint Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective
    Joel W Hay
    University of Southern California Center for the Health Professions, Los Angeles, CA 90033, USA
    Curr Med Res Opin 25:1421-31. 2009
    ..To review the pharmacoeconomic literature evaluating use of antihistamines in treating allergic rhinitis (AR) in the US...
  10. doi request reprint Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I
    Joel W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089 9004, USA
    Value Health 13:3-7. 2010
    ..The objective of this report is to provide guidance and recommendations on how drug costs should be measured for CEAs performed from a number of key analytic perspectives...
  11. doi request reprint Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment
    Joel Hay
    University of Southern California, Los Angeles, California, USA
    Allergy Asthma Proc 30:634-42. 2009
    ..These differences persisted after adjustment for patient fixed effects, available confounders, and treatment propensity scores...
  12. doi request reprint Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors
    J W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA
    Haemophilia 17:e969-74. 2011
    ..First-line APCC compared with rFVIIa can be a cost-saving alternative for home treatment of mild-to-moderate bleeds in haemophilia patients with inhibitors...
  13. doi request reprint Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa
    Joel W Hay
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089, USA
    J Med Econ 14:516-25. 2011
    ....
  14. ncbi request reprint Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089, USA
    Pharmacoeconomics 23:133-41. 2005
    ..Fibrates, particularly gemfibrozil, have been shown to raise HDL-cholesterol levels and reduce the incidence of CHD. The literature on fibrate cost effectiveness is quite limited...
  15. ncbi request reprint The cost effectiveness of cardiovascular medicines
    Joel Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Center for the Health Professions CHP 140, 1540 E Alcazar Street, Los Angeles, CA 90089, USA
    Curr Atheroscler Rep 7:79-80. 2005
  16. ncbi request reprint Hospital cost drivers: an evaluation of 1998-2001 state-level data
    Joel W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, Calif 90089, USA
    Am J Manag Care 9:SP13-24. 2003
    ..To evaluate the determinants of increased hospital inpatient expenditure growth since 1998...
  17. doi request reprint Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer
    Quang A Le
    Department of Clinical Pharmacy, Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089 9004, USA
    Cancer 115:489-98. 2009
    ..The objective of the current analysis was to assess the cost-effectiveness of this therapy from the US societal perspective...
  18. ncbi request reprint Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
    J W Hay
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, USA
    Pharmacoeconomics 15:47-74. 1999
    ..But any proven opportunity for saving the lives of 25% of those dying from cardiovascular disease each year deserves to be considered with the utmost seriousness and urgency...
  19. ncbi request reprint Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure
    Lei Chen
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA 90089, USA
    Cardiovasc Drugs Ther 18:161-70. 2004
    ..Implanted cardioverter defibrillator (ICD) is expensive but highly effective in preventing sudden death. The value of primary prophylactic ICD in preventing sudden death for congestive heart failure patients (CHF) has not been established...
  20. ncbi request reprint Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine
    Lihua Zhang
    Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089, USA
    CNS Drugs 19:635-42. 2005
    ..It has been shown that triptans are more efficacious than ergotamine, but the higher acquisition costs and shorter duration of action are disadvantages of triptans compared with ergotamine...
  21. ncbi request reprint Understanding the underlying drivers of inpatient cost growth: a literature review
    Mireille M Goetghebeur
    BioMedCom Consultants Inc, Montreal, Quebec, Canada
    Am J Manag Care 9:SP3-12. 2003
    ..Understanding the underlying reasons for this new growth will aid decision makers in finding best means to manage inpatient costs...
  22. ncbi request reprint Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis
    Kenneth W Purdy
    University of California Los Angeles UCLA Center for Vaccine Research, Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502 2502, USA
    Clin Infect Dis 39:20-8. 2004
    ..A recommendation for booster vaccinations every 10 years requires more information about duration of immunity, program costs, compliance, and nonmedical costs associated with pertussis...
  23. doi request reprint Asthma costs and utilization in a managed care organization
    Robert S Zeiger
    Department of Allergy, Kaiser Permanente Medical Center, 7060 Clairemont Mesa Blvd, San Diego, CA 92111, USA
    J Allergy Clin Immunol 121:885-92.e5. 2008
    ..Medical costs and health care utilization associated with asthma and the variation by treatment are poorly understood...
  24. ncbi request reprint Expensive conditions
    Joel W Hay
    Health Aff (Millwood) 21:271-2; author reply 272. 2002
  25. ncbi request reprint Where's the value in health care?
    Joel W Hay
    Value Health 9:141-3. 2006
  26. ncbi request reprint Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program
    Lida R Etemad
    Economic and Outcomes Research, Ingenix, Eden Prairie, MN, USA
    Value Health 6:425-35. 2003
    ..Using a societal perspective, we evaluated the impact pharmacists could have on inappropriate prescribing, patient compliance, and medication-related morbidity and mortality within a Medicare drug benefits program...
  27. ncbi request reprint Development and validation of a grading system for the quality of cost-effectiveness studies
    Chiun Fang Chiou
    Zynx Health Inc, Cerner Corporation, Beverly Hills, California 90212, USA
    Med Care 41:32-44. 2003
    ..To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies...
  28. ncbi request reprint Effects of ambulatory-care pharmacist consultation on mortality and hospitalization
    Yong Yuan
    Global Epidemiology Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
    Am J Manag Care 9:45-56. 2003
    ..To determine the effect of 3 alternative models of ambulatory-care pharmacist consultation on patient survival and hospitalization...
  29. ncbi request reprint Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide
    Joel W Hay
    J Manag Care Pharm 11:344-8. 2005
  30. ncbi request reprint Examining the value and quality of health economic analyses: implications of utilizing the QHES
    Joshua J Ofman
    Zynx Health Inc, 9100 Wilshire Blvd, East Tower, Suite 655, Beverly Hills, CA 90212, USA
    J Manag Care Pharm 9:53-61. 2003
    ..To examine the increasing use of health economic studies and practical implications of evaluating their quality utilizing the Quality of Health Economic Studies (QHES) instrument...
  31. ncbi request reprint Evaluating the cost-effectiveness of statins
    Joel W Hay
    J Manag Care Pharm 10:79-81. 2004
  32. ncbi request reprint A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Kimbach T Carpiuc
    Pharmerit North America LLC, 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland 20814, USA
    Expert Opin Pharmacother 8:2775-87. 2007
    ....
  33. ncbi request reprint Comparing patient access to pharmaceuticals in the UK and US
    Joel W Hay
    Appl Health Econ Health Policy 5:269-70; author reply 270-2. 2006
  34. ncbi request reprint Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature
    Jennifer M Stephens
    Pharmerit North America, LLC, 7272 Wisconsin Ave, Suite 300, Bethesda, Maryland 20814, USA
    J Manag Care Pharm 12:130-42. 2006
    ..To review the recent literature (January 2000-November 2005) regarding the impact of antidiabetic medications and glycemic control on the overall costs of care for patients with diabetes in U.S. managed care organizations (MCOs)...